More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.
The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
